U.S. Homeland Security Pharmaceuticals & Chemicals R&D -Programs and Funding Opportunities

Table of Contents

1. Executive Summary

• 1.1. Introduction
• 1.2. Basic Scenario Assumptions
• 1.3. Methodology
• 1.4. Major Research Findings
  • 1.4.1. U.S. HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 1.4.2. U.S. HLS Pharmaceuticals R&D Market Forecast - 2006- 2010
• 1.5. Major Research Conclusions

2. U.S. HLS Pharmaceuticals R&D Funding Opportunities - 2006 - 2010

• 2.1. U.S. Homeland Security R&D Structure
  • 2.1.1. Definitions
• 2.2. U.S. HLS Pharmaceuticals R&D - Participating Agencies & Funding - 2006- 2010
• 2.3. U.S. HLS Pharmaceuticals R&D Outlay - Overview 2006 - 2010
• 2.4. U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 2.5. U.S. HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 2.6. U.S. HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010

3. DHHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• 3.1. NIH (DHHS) - Homeland Security Mission
• 3.2. CDC (DHHS) - Homeland Security Mission
• 3.3. FDA (DHHS) - Homeland Security Mission
• 3.4. DHHS - HLS Pharmaceuticals R&D Program Summary & Budget Forecast - 2006- 2010
  • 3.4.1. DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application - 2006- 2010
• 3.5. DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 3.6. DHHS - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 3.7. DHHS - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010

4. DOD - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• 4.1. DOD - General Structure of R&D Budget & Fund Allocations
• 4.2. DOD - R&D Policy Making Hierarchy
• 4.3. U.S. ARMY - R&D Funding Agencies
  • 4.3.1. U.S. ARMY Research Office (ARO)
  • 4.3.2. U.S. ARMY Research Laboratory (ARL)
• 4.4. DOD - Defense Advanced Research Projects Agency (DARPA)
• 4.5. DOD - Chemical and Biological Defense Program (CBDP)
• 4.6. DOD - HLS Pharmaceuticals R&D Program Summary & Budget Forecast - 2006- 2010
  • 4.6.1. DOD - HLS Pharmaceuticals R&D Budget Forecast by Application - 2006- 2010
  • 4.6.2. DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency - 2006- 2010
• 4.7. DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 4.8. DOD - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 4.9. DOD - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010

5. DHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• 5.1. Outline and Resources
• 5.2. DHS - Science & Technology Division (S&T)
• 5.3. S&T Directorate - Major Groups
  • 5.3.1. DHS - Office of Programs Plans & Budgets (PPB)
  • 5.3.2. DHS - Homeland Security Advanced Research Projects Agency (HSARPA)
  • 5.3.3. DHS - Office of R&D
  • 5.3.4. DHS - Office of Systems Engineering and Development (SED)
• 5.4. DHS - HLS Pharmaceuticals R&D Program Summary & Budget Forecast - 2006- 2010
• 5.5. DHS - Pharmaceuticals R&D Budget Forecast by Application - 2006- 2010
• 5.6. DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
  • 5.6.1. Allocation to Private, Academia & Government Sectors - 2006 - 2010
• 5.7. DHS - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 5.8. DHS - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010

6. DOE - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• 6.1. DOE - HLS R&D Sources
• 6.2. DOE - HLS Pharmaceuticals R&D Program Summary & Budget Forecast - 2006- 2010
• 6.3. DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 6.4. DOE - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 6.5. DOE - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010

7. USDA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• 7.1. USDA - HLS R&D Sources
• 7.2. USDA - HLS Pharmaceuticals R&D Program Summary & Budget Forecast - 2006- 2010
• 7.3. USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 7.4. USDA - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 7.5. USDA - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010

8. EPA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• 8.1. EPA - HLS R&D Sources
• 8.2. EPA - HLS Pharmaceuticals R&D Program Summary & Budget Forecast - 2006- 2010
  • 8.2.1. EPA - HLS Pharmaceuticals R&D Budget Forecast by Application - 2006- 2010
• 8.3. EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 8.4. EPA - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 8.5. EPA - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010

9. Biological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 9.1. Summary & Outlook
• 9.2. Biological Therapeutics - HLS R&D Budget Forecast by Major Departments - 2006- 2010
  • 9.2.1. DHHS - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 9.2.2. DOD - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• 9.3. Biological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006 - 2010
• 9.4. Biological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 9.5. Biological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010
• 9.6. NIH & NIAID (DHHS) - Biological Therapeutics HLS Pharmaceuticals R&D Programs
  • 9.6.1. Category A Agents: Development of Biomedical Measures
• 9.7. DARPA (DOD) - Biological Therapeutics HLS Pharmaceuticals R&D Programs
  • 9.7.1. Unconventional Therapeutics
• 9.8. CBDP (DOD) - Biological Therapeutics HLS Pharmaceuticals R&D Programs
  • 9.8.1. Project TB1 Medical Biological Defense (Basic Research) - Therapeutics
  • 9.8.2. Project TB2 Medical Biological Defense (Applied Research) - Therapeutics
  • 9.8.3. Project TB3 Medical Biological Defense (ATD)

10. Vaccines - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 10.1. Summary & Outlook
• 10.2. Vaccines - HLS Pharmaceuticals R&D Budget Forecast by Major Departments - 2006- 2010
  • 10.2.1. DHHS - Vaccines HLS Pharmaceuticals R&D
  • 10.2.2. DOD - Vaccines HLS Pharmaceuticals R&D
• 10.3. Vaccines - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 10.4. Vaccines - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 10.5. Vaccines - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010
• 10.6. NIH & NIAID (DHHS) - Vaccines HLS Pharmaceuticals R&D Programs
  • 10.6.1. Category A Agents: Development of Biomedical Measures
  • 10.6.2. Category B and C Priority Pathogens and Toxins
• 10.7. ARMY (DOD) - Vaccines HLS Pharmaceuticals R&D Programs
  • 10.7.1. Medical Technology - Infectious Diseases
  • 10.7.2. Medical Advanced Technology - Infectious Diseases
• 10.8. CBDP (DOD) - Vaccines HLS Pharmaceuticals R&D Programs
  • 10.8.1. Project TB1 Medical Biological Defense (Basic Research) - Vaccines
  • 10.8.2. Project TB2 Medical Biological Defense (Applied Research) - Vaccines
  • 10.8.3. Project TB3 Medical Biological Defense (ATD) - Vaccines
  • 10.8.4. Project MB4 Medical Biological Defense (ACD&P) - Vaccines
  • 10.8.5. Project MB5 Medical Biological Defense (SDD) - Vaccines

11. Chemical Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 11.1. Summary & Outlook
• 11.2. DOD - Chemical Therapeutics - HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• 11.3. Chemical Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006 - 2010
• 11.4. Chemical Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006 - 2010
• 11.5. Chemical Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006 - 2010
• 11.6. CBDP (DOD) - Chemical Therapeutics - HLS Pharmaceuticals R&D Programs
  • 11.6.1. Project TC1 Medical Chemical Defense (Basic Research) - Therapeutics
  • 11.6.2. Project TC2 Medical Chemical Defense (Applied Research) - Therapeutics
  • 11.6.3. Project TC2 Medical Chemical Defense (Applied Research) - Pretreatments
  • 11.6.4. Project TC3 Medical Chemical Defense (ATD) - Therapeutics
  • 11.6.5. Project TC3 Medical Chemical Defense (ATD) - Pretreatments
  • 11.6.6. Project MC4 Medical Chemical Defense (ACD&P) - Therapeutics
  • 11.6.7. Project MC4 Medical Chemical Defense (ACD&P)

12. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 12.1. Summary & Outlook
• 12.2. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D by Major Departments Forecast - 2006- 2010
  • 12.2.1. NIH (DHHS) - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 12.2.2. DOD - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 12.2.3. DOE - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• 12.3. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 12.4. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 12.5. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010
• 12.6. NIH (DHHS) - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs
  • 12.6.1. Therapeutics for Radiation Damage
• 12.7. CBDP (DOD) - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs
  • 12.7.1. Project TR2 Medical Radiological Defense (Applied Research)
  • 12.7.2. Project TR3 Medical Radiological Defense (ATD)
  • 12.7.3. Project MR4 Medical Radiological Defense
• 12.8. DOE - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs
  • 12.8.1. Low Dose Radiation research

13. Decontamination - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 13.1. Summary & Outlook
• 13.2. Decontamination - HLS Pharmaceuticals R&D by Major Departments Forecast - 2006- 2010
  • 13.2.1. EPA - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 13.2.2. DOD - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 13.2.3. DHS - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 13.2.4. DOE - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 13.2.5. TSWG - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• 13.3. Decontamination - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 13.4. Decontamination - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 13.5. Decontamination HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010
• 13.6. DHS - Decontamination HLS Pharmaceuticals R&D Programs
  • 13.6.1. Response and Recovery
  • 13.6.2. Decontamination of Porous Surfaces after a Radiological Attack
  • 13.6.3. Expedient Mitigation of a Radiological Release
• 13.7. DARPA (DOD) - Decontamination HLS Pharmaceuticals R&D Programs
  • 13.7.1. Immune Buildings
  • 13.7.2. External protection
• 13.8. CBDP (DOD) - Decontamination HLS Pharmaceuticals R&D Programs
  • 13.8.1. Project CB1 - Decontamination
  • 13.8.2. Project CB2 - Decontamination
  • 13.8.3. Project CB3 Biological Defense (ATD) - Decontamination
  • 13.8.4. Project DE4 Decontamination Systems (ACD&P)
  • 13.8.5. Project DE5 Decontamination Systems (SDD)
• 13.9. ARMY (DOD) - Decontamination HLS Pharmaceuticals R&D Programs
  • 13.9.1. Environmental Quality Technology
• 13.10. DOE - Decontamination HLS Pharmaceuticals R&D Programs
  • 13.10.1. Environmental Remediation Science Research
• 13.11. EPA - Decontamination HLS Pharmaceuticals R&D Programs
  • 13.11.1. Water Infrastructure Decontamination
  • 13.11.2. Threat and Consequence Assessment
  • 13.11.3. Nonstandard Methods
  • 13.11.4. Decontamination for Buildings, Large Structures, and Outdoor Areas
  • 13.11.5. Toxicity, Infectivity, and Mechanism of Action
• 13.12. TSWG - Decontamination HLS Pharmaceuticals R&D Programs
  • 13.12.1. Statistical Design Tool for Sampling Contaminated Buildings
  • 13.12.2. Decontamination

14.Diagnostics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 14.1. Summary & Outlook
• 14.2. Diagnostics - HLS Pharmaceuticals R&D by Major Departments Budget Forecast - 2006- 2010
  • 14.2.1. DHHS - Diagnostics HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 14.2.2. DOD - Diagnostics HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• 14.3. Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 14.4. Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 14.5. Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010
• 14.6. NIH & NIAID (DHHS) - Diagnostics HLS Pharmaceuticals R&D Programs
  • 14.6.1. Category A Agents: Development of Diagnostic Measures
• 14.7. ARMY (DOD) - Diagnostics HLS Pharmaceuticals R&D Programs
  • 14.7.1. Infectious Diseases
• 14.8. DARPA (DOD) - Diagnostics HLS Pharmaceuticals R&D Programs
  • 14.8.1. Advanced Diagnostics
• 14.9. CBDP (DOD) - Diagnostics HLS Pharmaceuticals R&D Programs
  • 14.9.1. Project TB1 Medical Biological Defense (Basic Research) - Diagnostics
  • 14.9.2. Project TB2 Medical Biological Defense (Applied Research) - Diagnostics
  • 14.9.3. Project TB3 Medical Biological Defense (ATD) - Diagnostics
  • 14.9.4. Project MB5 Medical Biological Defense (SDD) - Diagnostics
  • 14.9.5. Project TC1 Medical Chemical Defense (Basic Research) - Diagnostics
  • 14.9.6. Project TC2 Medical Chemical Defense (Applied Research) - Diagnostics
  • 14.9.7. Project TC3 Medical Chemical Defense (ATD) - Diagnostics

15. Food Protection Treatments - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 15.1. Summary & Outlook
• 15.2. Food Protection Treatments - HLS Pharmaceuticals R&D by Major Departments Forecast - 2006- 2010
  • 15.2.1. DHHS - Food Protection Treatments HLS Pharmaceuticals R&D Forecast - 2006- 2010
  • 15.2.2. USDA - Food Protection Treatments HLS Pharmaceuticals R&D Forecast - 2006- 2010
  • 15.2.3. DHS - Food Protection Treatments HLS Pharmaceuticals R&D Forecast - 2006- 2010
• 15.3. Food Protection Treatments - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 15.4. Food Protection Treatments - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 15.5. Food Protection Treatments - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010
• 15.6. DHS - Food Protection Treatments HLS Pharmaceuticals R&D Programs
  • 15.6.1. Agriculture
• 15.7. FDA (DHHS) - Food Protection Treatments HLS Pharmaceuticals R&D Programs
  • 15.7.1. Food Defense Research
• 15.8. USDA - Food Protection Treatments HLS Pharmaceuticals R&D Programs
  • 15.8.1. Livestock Protection
• 15.9. NIH (DHHS) - Food Protection Treatments HLS Pharmaceuticals R&D Programs
  • 15.9.1. Food and Water-Borne Diseases

16. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• 16.1. Summary & Outlook
• 16.2. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Budget Forecast by Major Departments- 2006- 2010
  • 16.2.1. DHHS - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 16.2.2. DOD - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 16.2.3. DHS - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
  • 16.2.4. NSF - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• 16.3. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Funding Opportunities Forecast - 2006- 2010
• 16.4. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Funding Opportunities Drivers - 2006- 2010
• 16.5. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Funding Opportunities Inhibitors - 2006- 2010.
• 16.6. DHS - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs
  • 16.6.1. Threat Awareness and Characterization
  • 16.6.2. Forensics
• 16.7. NIH & NIAID (DHHS) - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs
  • 16.7.1. Sequencing of Microorganisms
  • 16.7.2. Developing Research Tools
  • 16.7.3. Understanding, Assessing, and Enhancing Host Immunity
• 16.8. CDC (DHHS) - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs
  • 16.8.1. Reduce the Spread of Anti-Microbial Resistance
• 16.9. DARPA (DOD) - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs
  • 16.9.1. Biological Adaptation, Assembly, and Manufacture
  • 16.9.2. Nanostructure in Biology
• 16.10. CBDP (DOD) - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs
  • 16.10.1. Project CB1 Biological Defense (Basic Research) - Other
  • 16.10.2. Project TB1 Medical Biological Defense (Basic Research) - Multi-Agent Medical Countermeasures
  • 16.10.3. Project TB2 Medical Biological Defense (Applied Research) Emerging Threats
  • 16.10.4. Project TB3 Medical Biological Defense (ATD) - Emerging Threats
  • 16.10.5. Project MB5 Medical Biological Defense (SDD) - Critical Reagents Program (CRP)
  • 16.10.6. Project TC1 Medical Chemical Defense (Basic Research) - Emerging Threats
  • 16.10.7. Project TC2 Medical Chemical Defense (Applied Research) Emerging Threats
  • 16.10.8. Project TC3 Medical Chemical Defense (ATD) - Emerging Threats
  • 16.10.9. Project CB2 Chemical Defense (Applied Research) - Threat Agent Sciences
• 16.11. NSF - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Programs
  • 16.11.1. Fundamental Research to Enhance Homeland Security

17. Investing In HLS Technology

• 17.1. A Word of Caution
• 17.2. HLS Industry Experts
• 17.3. Competitive Intelligence
• 17.4. A Second Opinion

Appendix A: The Homeland Security Federal R&D Infrastructure

• A.1. SBIR (Small Business Innovations Research) R&D Funding
• A.2. STTR (Small Business Technology Transfer Program) R&D Funding

1. Executive Summary

• Figure 1 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application [ $B ] - 2006- 2010
• Figure 2 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application Share - 2004, 2006 & 2010
• Figure 3 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $B ] - 2006- 2010
• Figure 4 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010

2. U.S. HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Figure 5 - Overview of Entire Homeland Security and Homeland Defense Infrastructure
• Figure 6 - U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency [ $B ] - 2006- 2010
• Figure 7 - Federal HLS Pharmaceuticals R&D Budget Forecast by Agency Share - 2004, 2006 & 2010
• Figure 8 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $B ] - 2006- 2010
• Figure 9 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 10 - U.S. HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $B ] - 2006- 2010
• Figure 11 - U.S. HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $B ] - 2006- 2010
• Figure 12 - U.S. HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [ $B ] - 2006- 2010

3. DHHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Figure 13 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application [ $B ] - 2006- 2010
• Figure 14 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application Share - 2004, 2006 & 2010
• Figure 15 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $B ] - 2006- 2010
• Figure 16 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 17 - DHHS - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 18 - DHHS - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 19 - DHHS - HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010

4. DOD - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010 Figure 20 - DOD - R&D Oversight and Funding Allocation

• Figure 21 - DOD - Historical Trends in Defense R&D [ $B ] - 2000 - 2006
• Figure 22 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application [ $M ] - 2006- 2010
• Figure 23 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application - 2004, 2006 & 2010
• Figure 24 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency [ $M ] - 2006- 2010
• Figure 25 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency Share - 2004, 2006 & 2010
• Figure 26 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 27 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 28 - DOD - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 29 - DOD - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 30 - DOD - HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010

5. DHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Figure 31 - DHS - Science and Technology Division (S&T) - Organizational Chart
• Figure 32 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application [ $B ] - 2006- 2010
• Figure 33 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application Share - 2004, 2006 & 2010
• Figure 34 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $B ] - 2006- 2010
• Figure 35 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 36 - DHS - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 37 - DHS - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 38 - DHS - HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [ $M ] - 2006- 2010

6. DOE - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Figure 39 - DOE - HLS Pharmaceuticals R&D Funding Summary Forecast [ $M ] - 2006- 2010
• Figure 40 - DOE - HLS Pharmaceuticals R&D Budget Forecast by Application Share - 2004, 2006 & 2010
• Figure 41 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 42 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 43 - DOE - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 44 - DOE - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 45 - DOE - HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [ $M ] - 2006- 2010

7. USDA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Figure 46 - USDA - Food and Water Treatment R&D Budget Forecast [ $B ] - 2006- 2010
• Figure 47 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 48 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 49 - USDA - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 50 - USDA - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 51 - USDA - HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [ $M ] - 2006- 2010

8. EPA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Figure 52 - EPA - Decontamination R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 53 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 54 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 55 - EPA - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 56 - EPA - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 57 - EPA - HLS Pharmaceuticals R&D Government Funding Opportunities Forecast [ $M ] - 2006- 2010

9. Biological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 58 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Figure 59 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share - 2004, 2006 & 2010
• Figure 60 - DHHS - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 61 - DOD - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 62 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 63 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 64 - Biological Therapeutics HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 65 - Biological Therapeutics HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 66 - Biological Therapeutics HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 67 - Unconventional Therapeutics - Program Funding [ $M ] - 2004- 2007
• Figure 68 - Project TB1 Medical Biological Defense (Basic Research) Therapeutics - Program Funding [ $M ] - 2004 - 2010
• Figure 69 - Project TB2 Medical Biological Defense (Applied Research) Therapeutics - Program Funding [ $M ] - 2004- 2007
• Figure 70 - Project TB3 Medical Biological Defense (ATD) - Program Funding [ $M ] - 2004- 2007

10. Vaccines - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 71 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $B ] - 2006- 2010
• Figure 72 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share - 2004, 2006 & 2010
• Figure 73 - DHHS - Vaccines HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 74 - DOD - Vaccines HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 75 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $B ] - 2006- 2010
• Figure 76 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 77 - Vaccines HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 78 - Vaccines HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 79 - Vaccines HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 80 - Scrub Typhus Vaccine - Program Funding [ $M ] - 2004 - 4007
• Figure 81 - Vaccines against Dengue Fever, Meningitis and Hemorrhagic Fevers - Program Funding [ $M ] - 2004- 2007
• Figure 82 - Dengue, Meningitis and Hemorrhagic Fever with Renal Syndrome (HFRS) Vaccines - Program Funding [ $M ] - 2004- 2010
• Figure 83 - Project TB1 Medical Biological Defense (Basic Research) - Vaccines - Program funding [ $M ] - 2004- 2007
• Figure 84 - Project TB2 Medical Biological Defense (Applied Research) - Vaccines - Program Funding [ $M ] - 2004- 2007
• Figure 85 - Project TB3 Medical Biological Defense (Applied Research) - Vaccines - Program Funding [ $M ] - 2004- 2007
• Figure 86 - Project MB4 Medical Biological Defense (ACD&P) - Botulinum Vaccine - Program Funding [ $M ] - 2004- 2006
• Figure 87 - Project MB4 Medical Biological Defense (ACD&P) - Encephalitis Vaccine - Program Funding [ $M ] - 2004- 2006
• Figure 88 - Project MB4 Medical Biological Defense (ACD&P) - Plague Vaccine - Program Funding [ $M ] - 2004- 2006
• Figure 89 - Project MB5 Medical Biological Defense (SDD) - Botulinium Vaccine - Program Funding [ $M ] - 2004- 2007
• Figure 90 - Project MB5 Medical Biological Defense (SDD) - Plague Vaccine - Program Funding [ $M ] - 2004- 2007

11. Chemical Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 91 - DOD - Chemical Therapeutics HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 92 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 93 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 94 - Chemical Therapeutics - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 95 - Chemical Therapeutics - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 96 - Chemical Therapeutics - HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 97 - Project TC1 Medical Chemical Defense (Basic Research) - Therapeutics - Program Funding [ $M ] - 2004- 2007
• Figure 98 - Nerve Agent Defense, Neuroprotection - Program Funding [ $M ] - 2004- 2007
• Figure 99 - Vesicant Agent Defense, Vesicant Medical Countermeasures- Program Funding [ $M ] - 2004- 2007
• Figure 100 - Chemical Warfare Agent Defense, Inhalation Therapeutics - Program Funding [ $M ] - 2004- 2007
• Figure 101 - Project TC2 Medical Chemical Defense (Applied Research) - Therapeutics - Program Funding [ $M ] - 2004- 2007
• Figure 102 - Project TC2 Medical Chemical Defense (Applied Research) - Pretreatments - Program Funding [ $M ] - 2004- 2007
• Figure 103 - Project TC3 Medical Chemical Defense (ATD) - Therapeutics - Program Funding [ $M ] - 2004- 2007
• Figure 104 - Project TC3 Medical Chemical Defense (ATD) - Therapeutics - Anti-Convulsants - Program Funding [ $M ] - 2004- 2007
• Figure 105 - Project TC3 Medical Chemical Defense (ATD) - Neuroprotectors - Program Funding [ $M ] - 2004- 2007
• Figure 106 - Project TC3 Medical Chemical Defense (ATD) - Vesicant Agent Defense - Program Funding [ $M ] - 2004- 2007
• Figure 107 - Project TC3 Medical Chemical Defense (ATD) - Therapeutics - Skin and Wound Decontamination - Program Funding [ $M ] - 2004- 2007
• Figure 108 - Project TC3 Medical Chemical Defense (ATD) - Pretreatments - Program Funding [ $M ] - 2004- 2007
• Figure 109 - Project MC4 Medical Chemical Defense (ACD&P) - Therapeutics - Program Funding [ $M ] - 2004- 2007
• Figure 110 - Project MC4 Medical Chemical Defense (ACD&P) - Program Funding [ $M ] - 2004- 2007

12. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 111 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $B ] - 2006- 2010
• Figure 112 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share - 2004, 2006 & 2010
• Figure 113 - NIH (DHHS) - Nuclear/Radiological Countermeasures HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 114 - DOD - Nuclear/Radiological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 115 - DOE - Nuclear/Radiological Therapeutics HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 116 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 117 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 118 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 119 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 120 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 121 - Project TR2 Medical Radiological Defense - Program Funding [ $M ] - 2004- 2007
• Figure 122 - Project TR3 Medical Radiological Defense - Program Funding [ $M ] - 2004- 2011
• Figure 123 - Project MR4 Medical Radiological Defense - Program Funding [ $M ] - 2004- 2011
• Figure 124 - Low Dose Radiation Research - Program Funding [ $M ] - 2004- 2006

13. Decontamination - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 125 - Decontamination - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Figure 126 - Decontamination- HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share - 2004, 2006 & 2010
• Figure 127 - EPA - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• Figure 128 - DOD - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• Figure 129 - DHS - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• Figure 130 - DOE - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• Figure 131 - TSWG - Decontamination HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• Figure 132 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 133 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 134 - Decontamination HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 135 - Decontamination HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 136 - Decontamination HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 137 - Immune Buildings - Program Funding [ $M ] - 2004-2007
• Figure 138 - External Protection Funding [ $M ] - 2004- 2007
• Figure 139 - Project CB1 - Decontamination - Program Funding [ $M ] - 2004 - 2007
• Figure 140 - Project CB2 - Decontamination - Program Funding [ $M ] - 2004 - 2007
• Figure 141 - Project CB3 Biological Defense (ATD) - Decontamination - Program Funding [ $M ] - 2004 - 2007
• Figure 142 - Project DE4 Decontamination Systems (ACD&P) - Program Funding [ $M ] 2004 - 2011
• Figure 143 - Project DE5 Decontamination Systems (SDD) - Program Funding [ $M ] - 2004 - 2011
• Figure 144 - Industrial Operational Pollution Control Technology - Program Funding [ $M ] - 2004 - 2007
• Figure 145 - Military Medical Environment - Program Funding [ $M ] - 2004 - 2007
• Figure 146 - Pollution Prevention - Program Funding [ $M ] - 2004 - 2007
• Figure 147 - Base Facility Environmental Quality - Program Funding [ $M ] - 2004 - 2007
• Figure 148 - Environmental Remediation Science Research - Program Funding [ $M ] - 2004- 2006

14. Diagnostics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 149 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments Budget
• Forecast [ $M ] - 2006- 2010
• Figure 150 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments Budget Forecast Share - 2004, 2006 & 2010
• Figure 151 - DHHS - Diagnostics HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 152 - DOD - Diagnostics HLS Pharmaceuticals R&D Budget Forecast - 2006- 2010
• Figure 153 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 154 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 155 - Diagnostics - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 156 - Diagnostics - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 157 - Diagnostics - HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 158 - Insect Vector Control and Infectious Disease - Diagnostics - Program Funding [ $M ] - 2004- 2007
• Figure 159 - Advanced Diagnostic - Program Funding [ $M ] - 2004- 2007
• Figure 160 - Project TB1 Medical Biological Defense (Basic Research) - Diagnostics - Program Funding [ $M ] - 2004- 2007
• Figure 161 - Project TB2 Medical Biological Defense (Applied Research) - Diagnostics - Program Funding [ $M ] - 2004- 2007
• Figure 162 - Project TB3 Medical Biological Defense (ATD) - Diagnostics - Program Funding [ $M ] - 2004- 2007
• Figure 163 - Project MB5 Medical Biological Defense (SDD) - Diagnostics - Program Funding [ $M ] - 2004- 2007
• Figure 164 - Project TC1 Medical Chemical Defense (Basic Research) - Diagnostics - Program Funding [ $K ] - 2004- 2007
• Figure 165 - Project TC2 Medical Chemical Defense (Applied Research) - Diagnostics - Program Funding [ $M ] - 2004- 2007
• Figure 166 - Project TC3 Medical Chemical Defense (ATD) - Diagnostics - Program Funding [ $K ] - 2004- 2007

15. Food Protection Treatments - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 167 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments Forecast - 2006- 2010
• Figure 168 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments Forecast Share - 2004, 2006 & 2010
• Figure 169 - DHHS - Food Protection Treatments HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 170 - USDA - Food Protection Treatments HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 171 - DHS - Food Protection Treatments HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 172 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 173 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 174 - Food Protection Treatments - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 175 - Food Protection Treatments - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 176 - Food Protection Treatments - HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 177 - Livestock Protection - Program Funding [ $M ] - 2004- 2007

16. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Figure 178 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Figure 179 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share - 2004, 2006 & 2010
• Figure 180 - DHHS - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 181 - DOD - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 182 - DHS - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 183 - NSF - Treatment for Emerging Biochemical Threats HLS Pharmaceuticals R&D Budget Forecast [ $M ] - 2006- 2010
• Figure 184 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Figure 185 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector - 2004, 2006 & 2010
• Figure 186 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Private Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 187 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Academia Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 188 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Government Sector Funding Opportunities Forecast [ $M ] - 2006- 2010
• Figure 189 - Biological Adaptation, Assembly & Manufacture - Program Funding [ $M ] - 2004-2007
• Figure 190 - Nanostructure in Biology - Program Funding [ $M ] - 2004- 2007
• Figure 191 - Project CB1 Biological Defense (Basic Research) - Other - Program Funding - 2004 - 2007
• Figure 192 - Project TB2 Medical Biological Defense (Applied Research) - Emerging Threats - Program Funding [ $M ] - 2004 - 2007
• Figure 193 - Project TB3 Medical Biological Defense (ATD) - Emerging Threats - Program Funding [ $M ] - 2004 - 2007
• Figure 194 - Project MB5 Medical Biological Defense (SDD) - Critical Reagents Program (CRP) - Program Funding [ $M ] - 2004 - 2007
• Figure 195 - Project TC1 Medical Chemical Defense (Basic Research) - Emerging Threats - Program Funding [ $M ] - 2004 - 2007
• Figure 196 - Non-Traditional Agents (NTAs) - Program Funding [ $M ] - 2004 - 2007
• Figure 197 - Project TC2 Medical Chemical Defense (Applied Research) - Emerging Threats - Program Funding [ $M ] - 2004 - 2007
• Figure 198 - Project TC3 Medical Chemical Defense (ATD) - Emerging Threats - Program Funding [ $M ] - 2004 - 2007
• Figure 199 - Project CB2 Chemical Defense (Applied Research) - Threat Agent Sciences - Program Funding [ $M ] - 2004 - 2007
• Appendix A: The Homeland Security Federal R&D Infrastructure Figure 200 - Homeland Security Federal R&D General Structure

1. Executive Summary

• Table 1 - HLS Pharmaceuticals R&D - Participating Agencies Funding for FY 2006 [ $M ]
• Table 2 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application [ $M ] - 2006- 2010
• Table 3 - U.S. HLS Pharmaceuticals R&D Budget Forecast by Application [ % ] - 2006- 2010
• Table 4 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 5 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector Share [ % ] - 2006- 2010

2. U.S. HLS Pharmaceuticals R&D Funding Opportunities - 2006 - 2010

• Table 6 - Major S&T Initiatives in the National Strategy for Homeland Security
• Table 7 - HLS Pharmaceuticals R&D - Participating Agencies and Programs for FY 2006-2010
• Table 8 - U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency [ $M ] - 2006- 2010
• Table 9 - U.S. Federal HLS Pharmaceuticals R&D Budget Forecast by Agency Share [ % ] - 2006- 2010
• Table 10 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 11 - U.S. HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector Share [ % ] - 2006- 2010

3. DHHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Table 12 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application [ $M ] - 2006- 2010
• Table 13 - DHHS - HLS Pharmaceuticals R&D Budget Forecast by Application Share [ % ] - 2006- 2010
• Table 14 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 15 - DHHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

4. DOD - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Table 16 - DOD - Research, Development, Test & Evaluation by Agency [ $B ] - 2004- 2006
• Table 17 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application [ $M ] - 2006- 2010
• Table 18 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Application Share [ % ] - 2006- 2010
• Table 19 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency [ $M ] - 2006- 2010
• Table 20 - DOD - HLS Pharmaceuticals R&D Budget Forecast by Agency Share [ % ] - 2006- 2010
• Table 21 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 22 - DOD - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

5. DHS - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Table 23 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application [ $M ] - 2006- 2010
• Table 24 - DHS - HLS Pharmaceuticals R&D Budget Forecast by Application Share [ % ] - 2006- 2010
• Table 25 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 26 - DHS - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

6. DOE - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Table 27 - DOE - HLS Pharmaceuticals R&D Funding Summary Forecast [ $M ] - 2006- 2010
• Table 28 - DOE - HLS Pharmaceuticals R&D Funding Summary Forecast Share [ % ] - 2006- 2010
• Table 29 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 30 - DOE - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

7. USDA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Table 31 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 32 - USDA - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

8. EPA - HLS Pharmaceuticals R&D Funding Opportunities - 2006- 2010

• Table 33 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 34 - EPA - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

9. Biological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 35 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Table 36 - Biological Therapeutics HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ % ] - 2006- 2010
• Table 37 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 38 - Biological Therapeutics HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

10. Vaccines - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 39 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Table 40 - Vaccines HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ % ] - 2006- 2010
• Table 41 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 42 - Vaccines HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

11. Chemical Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 43 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 44 - Chemical Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

12. Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 45 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Table 46 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ % ] - 2006- 2010
• Table 47 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 48 - Nuclear/Radiological Therapeutics - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

13. Decontamination - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 49 - Decontamination - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Table 50 - Decontamination - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ % ] - 2006- 2010
• Table 51 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 52 - Decontamination HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

14. Diagnostics - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 53 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments Budget Forecast [ $M ] - 2006- 2010
• Table 54 - Diagnostics - HLS Pharmaceuticals R&D by Major Departments Budget Forecast Share [ % ] - 2006- 2010
• Table 55 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 56 - Diagnostics - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

15. Food Protection Treatments - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 57 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments Forecast [ $M ] - 2006- 2010
• Table 58 - Food Protection Treatments HLS Pharmaceuticals R&D by Major Departments Forecast Share [ % ] - 2006- 2010
• Table 59 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 60 - Food Protection Treatments - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010

16. Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Programs and Funding Opportunities Forecast - 2006- 2010

• Table 61 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Budget Forecast by Major Departments [ $M ] - 2006- 2010
• Table 62 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Budget Forecast by Major Departments Share [ % ] - 2006- 2010
• Table 63 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Funding Opportunities Forecast by Sector [ $M ] - 2006- 2010
• Table 64 - Treatment for Emerging Biochemical Threats - HLS Pharmaceuticals R&D Funding Opportunities Forecast Share by Sector [ % ] - 2006- 2010
• Appendix A: The Homeland Security Federal R&D Infrastructure
• Table 65 - Small Business Innovation Research Program - FY2006
• Table 66 - Small Business Technology Transfer Program - FY2006